Xoma Corporation

Allergene, Inc.

Robert W Baldwin

Vera S Byers

Patrick J Scannon

Vera K Byers

The present invention provides novel compositions and methods useful in the, modulation or selective suppression of host immune responses to an immunogen of interest, particularly exogenous antigens and allergens such as urushiol, the active plant component causing poison ivy/oak contact sensitivity. The subject compositions are antibody molecules of either Ab.sub.1 or Ab.sub.2 (anti-idiotypic) reactivity with respect to the sensitizing antigen. Other compositions include specific T cell receptor (TCR) molecules either as T cell clones or hybridomas or as TCR preparations. Immunogenic peptides corresponding to some or all of the complementary determining regions or hyper-variable regions of the TCR are also employed. Such compositions suppress host immune responses to antigen by a variety of pathways including anti-idiotypic interactions with cells involved in antigen processing and stimulation of the immune network. T cell receptor molecules and immunogenic peptides corresponding to regions of the TCR also suppress immune responses by interactions with the immunoregulatory network.

Methods and compositions for the modulation of host immune response to

The present invention provides novel compositions and methods useful in the modulation or selective suppression of host immune responses to an immunogen of interest, particularly to immunogens which are exogenous antigens or allergens. Subject compositions include antibody, antibody derived, and antibody-like molecules of primary antigen reactivity with respect to the immunogen of interest. Antibodies or antibody-like or antibody-derived molecules include antibody fragments such as Fab, and complementarity determining region peptides (CDRs) which may be grafted into a framework region of any species, particularly human. They also include human antibodies, derived from sensitized human lymphocytes produced by cell fusion with heterohybridomas, or by DNA cloning and expression. Other compositions include T cell receptor (TCR) molecules, obtained either from T cell clones or hybridomas or as purified TCR preparations. Immunoreactive peptides corresponding to some or all of the complementarity determining regions or hypervariable regions of the TCR are also employed.

Methods for the selective suppression of an immune response to dust mite

Novel methods and compositions are provided for the enhancement of the biodistribution of immunoconjugates useful in the diagnosis and treatment of a variety of conditions including cancer in many of its forms. The compositions of the present invention provide for enhanced bioavailability of immunoconjugates for the most part by blocking mammalian cell surface receptors present on cells of the reticuloendothelial system, especially in tissues responsible for the elimination of waste products and blood filtration. Such tissues include the liver, spleen, and kidneys. The compositions are administered in conjunction with an immunoconjugate in a pharmaceutically acceptable vehicle and may be provided in kits for convenient administration.

Hepatic blocking agents

Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. For some of these compositions, an enhanced or potentiated efficacy is observed when the conjugates are administered along with a related, unconjugated monoclonal antibody. Hybridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively. Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.

Potentiation of cytotoxic conjugates

Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. Hydridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on Aug. 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively.

Ribosomal inhibiting protein-immunoglobulin conjugates with specificity

The present invention relates to the radioimmuno detection of cancers by detecting tumor associated antigens and comprising the following steps:

Growing community of inventors

Long Eaton, United Kingdom

Robert W Baldwin